latest news releases from the newsroom
Silverpop Completes Acquisition of Avalon's E-Mail Marketing Division
ATLANTA, July 7, 2003 (PRIMEZONE) -- Silverpop, a fast-growing provider of comprehensive e-mail marketing solutions, has completed its acquisition of the large enterprise business of Avalon Digital Marketing Systems (Nasdaq:AVLN), an Irvine, Calif.-based leader in customer communications software and services. The acquisition of these assets makes Silverpop one of the largest private companies in its industry and tremendously enhances the offerings of both organizations.
ViroPharma Announces Lead Compound Series with Potent Antiviral Activity Against Orthopoxviruses
EXTON, Pa., July 7, 2003 (PRIMEZONE) -- VIROPHARMA INCORPORATED (Nasdaq:VPHM) today announced that its scientists have discovered a lead compound series from VIROPHARMA's unique chemical library that shows potent and specific antiviral activity against orthopoxviruses, including monkeypox virus, at concentrations that have no adverse effects on normal cells in culture. Moreover, compounds in the series have been shown to be orally bioavailable in animal studies. VIROPHARMA is collaborating in this effort with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) in Frederick, Maryland. USAMRIID has confirmed the activity of the VIROPHARMA compounds against a range of orthopoxviruses and expects to determine, within the next few weeks, the activity of the compounds against the deadly variola (smallpox) virus in tests to be conducted at the Centers for Disease Control and Prevention (CDC) in Atlanta. Orthopoxviruses are a group of closely related viruses that include vaccinia, cowpox, monkeypox, camelpox and variola (smallpox) viruses.
Cordiant Communications Group PLC
Cordiant Communications Group (`Cordiant') -- Disposal of FD International
LONDON, July 7, 2003 (PRIMEZONE) -- Cordiant has entered into a conditional agreement to sell 100% of FD International, its business communications network, to new legal entities owned and financed principally by funds managed by Advent International, the global private equity firm. The purchase consideration is 26.0 million Pounds payable in cash at completion. The 26.0 million Pounds is subject to upwards or downwards adjustment based on a completion statement to be agreed or determined following completion. This transaction represents the final step in Cordiant's stated plan to reduce debt through a programme of non-core asset disposals. The net transaction proceeds will be applied to repay borrowings.
Astex Extends Research Collaboration with AstraZeneca
CAMBRIDGE, U.K., July 7, 2003 (PRIMEZONE) -- Astex Technology, the fragment-based drug discovery company, today announced that it has extended its existing research collaboration agreement with AstraZeneca AB (NYSE AZN) in the area of cytochrome P450s. Under the terms of the 3-year extension, Astex will continue to apply its high-throughput X-ray crystallography (HTX(R)) technology to obtain crystal structures of human cytochrome P450s alone and in complex with AstraZeneca's compounds. Financial details were not disclosed.